Melanoma: new insights and new therapies.

PubWeight™: 1.54‹?› | Rank: Top 4%

🔗 View Article (PMC 3759013)

Published in J Invest Dermatol on January 05, 2012

Authors

Vasiliki A Nikolaou1, Alexander J Stratigos, Keith T Flaherty, Hensin Tsao

Author Affiliations

1: Dermato-Oncology Unit, Department of Dermatology, University of Athens Medical School, Andreas Sygros Hospital, Athens, Greece.

Associated clinical trials:

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | NCT01400451

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | NCT01227889

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | NCT01245062

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients | NCT01337765

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | NCT01363232

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) | NCT01021748

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy | NCT00813423

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | NCT01143402

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain (Break MB) | NCT01266967

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma (CHIR-265-MEL01) | NCT00304525

PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER | NCT01037790

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | NCT01271803

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | NCT00667082

A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases | NCT01378975

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | NCT00827177

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma | NCT01320085

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM) | NCT01028222

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00470470

Lapatinib in Stage IV Melanoma With ERBB4 Mutations | NCT01264081

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations | NCT01099514

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT00349206

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | NCT01166126

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies | NCT00948467

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | NCT00866177

A Study of RO5185426 in Patients With Metastatic Melanoma | NCT01307397

Clinical Trial of Sutent to Treat Metastatic Melanoma | NCT00631618

A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours | NCT01143753

A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors | NCT00817518

A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma (STREAM) | NCT01377025

Study of XL281 in Adults With Solid Tumors | NCT00451880

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma | NCT00489944

NCT00859326

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | NCT01133977

Docetaxel With or Without AZD6244 in Melanoma (DOC-MEK) | NCT01256359

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma | NCT01136967

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma | NCT01216657

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL) | NCT01168050

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | NCT00788775

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | NCT01092728

A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit | NCT01280565

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | NCT00577382

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | NCT01107665

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma | NCT00492505

Dinaciclib in Treating Patients With Stage III-IV Melanoma | NCT01026324

Articles citing this

Mutational status of naevus-associated melanomas. Br J Dermatol (2015) 2.68

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer (2014) 1.79

Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum Pathol (2013) 1.50

UV radiation and the skin. Int J Mol Sci (2013) 1.37

Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36

Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res (2014) 1.27

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res (2013) 1.06

Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol (2013) 1.00

Epigenetic regulation in human melanoma: past and future. Epigenetics (2015) 0.98

A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms. J Invest Dermatol (2013) 0.97

Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol (2013) 0.92

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med (2013) 0.92

Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis (2013) 0.90

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One (2013) 0.90

Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88

Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87

St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death. PLoS One (2014) 0.87

Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22. Oncotarget (2016) 0.86

Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85

Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. Transl Oncol (2013) 0.83

PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1. J Invest Dermatol (2015) 0.83

Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell Death Dis (2012) 0.83

Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway. Cell Death Differ (2013) 0.82

Molecular mechanisms of garlic-derived allyl sulfides in the inhibition of skin cancer progression. Ann N Y Acad Sci (2012) 0.82

A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis (2012) 0.82

Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res (2013) 0.82

Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther (2012) 0.82

The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer. Carcinogenesis (2013) 0.80

Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus. Oncotarget (2014) 0.80

The immune-related role of BRAF in melanoma. Mol Oncol (2014) 0.78

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R. PLoS One (2014) 0.78

Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin. Oncotarget (2016) 0.78

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells. PLoS One (2015) 0.77

Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Des Devel Ther (2014) 0.77

Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med (2014) 0.77

Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep (2016) 0.75

Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biol Ther (2012) 0.75

Endoplasmic reticulum stress-induced autophagy determines the susceptibility of melanoma cells to dabrafenib. Drug Des Devel Ther (2016) 0.75

Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature. Case Rep Oncol (2013) 0.75

Climacostol reduces tumour progression in a mouse model of melanoma via the p53-dependent intrinsic apoptotic programme. Sci Rep (2016) 0.75

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer (2017) 0.75

Expression of Estrogen Receptor Alpha in Malignant Melanoma. Adv Biomed Res (2017) 0.75

miR-204-5p acts as a tumor suppressor by targeting matrix metalloproteinases-9 and B-cell lymphoma-2 in malignant melanoma. Onco Targets Ther (2017) 0.75

Long noncoding RNA ILF3-AS1 promotes cell proliferation, migration and invasion via negatively regulating miR-200b/a/429 in melanoma. Biosci Rep (2017) 0.75

Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells. Pharmacol Res (2017) 0.75

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Med J (2017) 0.75

Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor. J Cancer (2017) 0.75

Articles cited by this

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69

Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50

BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76

Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15

Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol (2004) 3.80

B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61

KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49

Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87

The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci U S A (1996) 2.68

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 2.58

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38

Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res (2007) 2.15

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.95

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol (2011) 1.77

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75

Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem (2008) 1.72

Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 1.68

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer (2009) 1.66

Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66

A novel transforming gene in a human malignant melanoma cell line. Nature (1984) 1.63

The INK4a/ARF locus and melanoma. Oncogene (2003) 1.57

Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res (2000) 1.55

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol (2008) 1.49

Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res (1992) 1.47

STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol (2002) 1.38

Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev (2007) 1.37

The genome and epigenome of malignant melanoma. APMIS (2007) 1.36

Activation of N-ras in a human melanoma cell line. Mol Cell Biol (1985) 1.30

Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene (1989) 1.30

Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res (2006) 1.26

Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ (2007) 1.24

Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res (1998) 1.18

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol (2011) 1.16

Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol (2003) 1.16

Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res (2000) 1.15

Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer (2003) 1.11

Melanoma and immunotherapy. Hematol Oncol Clin North Am (2009) 1.11

Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res (2011) 1.03

Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther (2007) 1.03

A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res (2010) 1.03

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med (2012) 0.97

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol (2010) 0.97

Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology (2008) 0.95

Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene (1999) 0.95

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol (2010) 0.94

Lonafarnib in cancer therapy. Expert Opin Investig Drugs (2006) 0.92

Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res (1996) 0.89

A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer (2010) 0.83

Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling. Biochim Biophys Acta (2001) 0.77

Evolving therapies: farnesyltransferase inhibitors. Curr Oncol Rep (2002) 0.76

Articles by these authors

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77

Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28

Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38

Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92

The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80

A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol (2002) 2.66

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51

High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat (2007) 2.35

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26

Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer (2013) 2.23

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11

BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol (2011) 2.10

Genetic alterations in signaling pathways in melanoma. Clin Cancer Res (2006) 2.00

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81

Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol (2011) 1.77

Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One (2012) 1.76

Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol (2008) 1.71

Vemurafenib. Nat Rev Drug Discov (2011) 1.68

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67

Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst (2014) 1.61

Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58

Phenotypic and genotypic analyses of genetic skin disease through the Online Mendelian Inheritance in Man (OMIM) database. J Invest Dermatol (2009) 1.57

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res (2009) 1.57

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer (2012) 1.54

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol (2008) 1.49

Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res (2011) 1.47

Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res (2012) 1.45

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol (2008) 1.35

Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol (2009) 1.30

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30

Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol (2010) 1.30

The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol (2008) 1.28

HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res (2007) 1.28

Cutaneous melanomas associated with nevi. Arch Dermatol (2003) 1.27

Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol (2009) 1.27

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res (2007) 1.26

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer (2013) 1.22

BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res (2012) 1.22

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer (2011) 1.21

Basal cell carcinoma: what's new under the sun. Photochem Photobiol (2010) 1.20

A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes. Exp Dermatol (2009) 1.18

Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst (2011) 1.17

Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin Cancer Res (2012) 1.17

A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer (2003) 1.17

Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol (2006) 1.17

Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17

BRAF in melanoma: current strategies and future directions. Clin Cancer Res (2013) 1.16

A melanoma molecular disease model. PLoS One (2011) 1.15

CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther (2013) 1.13

Small RNAs in development and disease. J Am Acad Dermatol (2008) 1.13

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology (2013) 1.13

Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res (2005) 1.12

New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 1.12

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest (2015) 1.11

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov (2013) 1.10

Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol (2005) 1.10

Ipilimumab for patients with advanced mucosal melanoma. Oncologist (2013) 1.09

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol (2012) 1.08

Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov (2011) 1.08

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol (2009) 1.08

Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res (2010) 1.08

Biological challenges of BRAF inhibitor therapy. Mol Oncol (2011) 1.08

Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res (2007) 1.07

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res (2012) 1.06